Frontlight ResearchEarly access
Duchenne muscular dystrophy trials in United States
20 of 35 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Enrolling by invitationA Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy
- Where
- Aurora, Cincinnati, Richmond
- People
- 20 worldwide
- Run by
- NS Pharma, Inc.
See details and how to joinNCT07943598 - Phase 4Taking peopleStudy to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
- Where
- Houston, Nashville
- Age
- 4 years and over
- People
- 20
- Run by
- Sarepta Therapeutics, Inc.
See details and how to joinNCT07542314 - Phase 1/2Taking peopleGlucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
- Where
- Nashville
- Age
- 18 years and over
- People
- 30
- Run by
- Vanderbilt University Medical Center
See details and how to joinNCT07642635 - Phase 1/2Taking peoplePBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
- Where
- Little Rock, St Louis
- Age
- 2 years to 7 years
- People
- 18
- Run by
- Precision BioSciences, Inc.
See details and how to joinNCT07429240 - Phase 2Enrolling by invitationAn Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
- Where
- Columbus, Los Angeles, Memphis, St Louis
- Age
- 16 years to 40 years
- People
- 30 worldwide
- Run by
- Satellos Bioscience, Inc.
See details and how to joinNCT06867107 - Phase 2Taking peopleEvaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
- Where
- Gainesville
- Age
- 6 years and over
- People
- 20
- Run by
- University of Florida
See details and how to joinNCT07766980 - Phase 3Not yet taking people in United StatesA Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
- Where
- Flower Mound, Little Rock, Norfolk
- Age
- 7 years to 11 years
- People
- 80 worldwide
- Run by
- Solid Biosciences Inc.
See details and how to joinNCT07160634 · EU 2025-522949-22-00 - Phase 2Enrolling by invitationOpen-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- Where
- Atlanta, Aurora, Austin, Baltimore, Chicago, Cincinnati, Columbus, Denton, Gainesville, Hillsborough, Indianapolis, Iowa City, Kansas City, La Jolla, Little Rock, Los Angeles, Orange, Palo Alto, Philadelphia, Richmond, Rochester, Sacramento, St Louis, Worcester
- People
- 260 worldwide
- Run by
- Edgewise Therapeutics, Inc.
See details and how to joinNCT06066580 - Phase 1Taking peopleA Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
- Where
- Chicago, Columbus, Durham, Flower Mound, Gainesville, La Jolla, Little Rock, Los Angeles, Norfolk, Palo Alto, Sacramento, St Louis
- Age
- 2 years and over
- People
- 83
- Run by
- Sarepta Therapeutics, Inc.
See details and how to joinNCT04626674 - Phase 1Taking peopleSodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
- Where
- Nashville
- Age
- 8 years to 18 years
- People
- 10
- Run by
- Vanderbilt University Medical Center
See details and how to joinNCT07172971 - Phase 4Taking peopleOnce Weekly Infant Corticosteroid Trial for DMD
- Where
- Chicago, Cincinnati, Columbus, Dallas
- Age
- 1 month to 30 months
- People
- 26
- Run by
- Anne M. Connolly
See details and how to joinNCT05412394 - No phaseEnrolling by invitationParent and Infant Inter(X)Action Intervention (PIXI)
- Where
- Research Triangle Park
- Age
- Up to 99 years
- People
- 120
- Run by
- RTI International
See details and how to joinNCT03836300 - Phase 1/2Taking peopleA Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
- Where
- Atlanta, Chicago, Columbus, Little Rock, Los Angeles, Norfolk, Philadelphia, Portland, Sacramento, San Diego, Seattle, St Louis
- Age
- 0 years to 17 years
- People
- 60 worldwide
- Run by
- Solid Biosciences Inc.
See details and how to joinNCT06138639 · EU 2024-514501-57-00 - Phase 3Taking peopleEfficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
- Where
- Hillsborough
- Age
- 4 years to 18 years
- People
- 90
- Run by
- Dyne Therapeutics
See details and how to joinNCT07608432 · EU 2025-524096-23-00 - Phase 2Taking peopleVasodilator and Exercise Study for DMD (VASO-REx)
- Where
- Gainesville
- Age
- 6 years and over
- People
- 50
- Run by
- University of Florida
See details and how to joinNCT06290713 - No phaseTaking peopleUrinary Titin Biomarker in DMD
- Where
- Philadelphia
- Age
- 2 years to 10 years
- People
- 50
- Run by
- Children's Hospital of Philadelphia
See details and how to joinNCT07332013 - Phase 1Taking peopleTrial of Cell Based Therapy for DMD
- Where
- Minneapolis
- Age
- 18 years and over
- People
- 8
- Run by
- Masonic Cancer Center, University of Minnesota
See details and how to joinNCT06692426 - Phase 3Enrolling by invitationA Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
- Where
- Aurora, Baltimore, Boston, Chicago, Columbus, Dallas, Durham, Gainesville, Iowa City, Little Rock, Los Angeles, Milwaukee, New York, Norfolk, Palo Alto, Philadelphia, Portland, Rochester, Sacramento, Salt Lake City, San Diego, St Louis
- Age
- Up to 64 years
- People
- 400 worldwide
- Run by
- Sarepta Therapeutics, Inc.
See details and how to joinNCT05967351 · EU 2023-505043-39-00 - Phase 2/3Enrolling by invitationGivinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- Where
- Atlanta, Gainesville, Hartford, Iowa City, Philadelphia, Portland, Richmond, Sacramento, San Diego, St Louis
- Age
- 7 years and over
- People
- 206 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT03373968 - Phase 1Taking peopleModulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
- Where
- Cincinnati, Columbus, Kansas City
- Age
- 18 years and over
- People
- 12
- Run by
- Sardocor Corp.
See details and how to joinNCT06224660